Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Aimovog

- PMLiVE

Novartis builds its case for novel MS treatment ofatumumab

Detailed results from phase 3 studies published in NEJM

- PMLiVE

AbbVie, Amgen and Takeda team up for joint COVID-19 trial

Collaborative trial will evaluate three anti-inflammatory drugs

- PMLiVE

Biogen plans Spinraza study in SMA patients treated with Novartis’ Zolgensma

Company aims to extend market reach

- PMLiVE

Novartis stumbles in Q2 as COVID-19 impacts sales

Net profit drops by 4% as pandemic hits sales

- PMLiVE

Novartis reveals plans for a zero-profit COVID-19 drugs portfolio

Includes 15 medicines from company's generics division

- PMLiVE

Novartis reveals full phase 3 results for Enerzair Breezhaler

Asthma treatment received EU approval earlier this week

- PMLiVE

Novartis forms coronavirus alliance with life sciences companies

Partnership will accelerate research with aid of Gates Foundation

- PMLiVE

Novartis says data backs safety of on-hold intrathecal Zolgensma

Data also demonstrated 'remarkable' efficacy in SMA type 2

Novartis day

Novartis donates malaria drug for COVID-19 clinical trials

Hydroxychloroquine will be evaluated for efficacy against novel coronavirus disease

- PMLiVE

Novartis launches $20m COVID-19 response fund

Financial grants will be issued to most impacted communities

- PMLiVE

Mergers and acquisitions: agents for change

Getting the best from your agency in a disruptive time

Bedrock Healthcare Communications

- PMLiVE

Biohaven gets FDA approval for migraine drug Nurtec ODT

Becomes second drugmaker to bring an oral CGRP inhibitor to US market

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links